Bierig Tobias, Collu Gabriella, Blanc Alain, Poghosyan Emiliya, Benoit Roger M
Laboratory of Nanoscale Biology, Division of Biology and Chemistry, Paul Scherrer Institute, Villigen, Switzerland.
Department of Biology, ETH Zürich, Zurich, Switzerland.
Front Bioeng Biotechnol. 2020 Dec 21;8:618615. doi: 10.3389/fbioe.2020.618615. eCollection 2020.
2019-nCoV is the causative agent of the serious, still ongoing, worldwide coronavirus disease (COVID-19) pandemic. High quality recombinant virus proteins are required for research related to the development of vaccines and improved assays, and to the general understanding of virus action. The receptor-binding domain (RBD) of the 2019-nCoV spike (S) protein contains disulfide bonds and N-linked glycosylations, therefore, it is typically produced by secretion. Here, we describe a construct and protocol for the expression and purification of yellow fluorescent protein (YFP) labeled 2019-nCoV spike RBD. The fusion protein, in the vector pcDNA 4/TO, comprises an N-terminal interferon alpha 2 (IFNα2) signal peptide, an eYFP, a FLAG-tag, a human rhinovirus 3C protease (HRV3C) cleavage site, the RBD of the 2019-nCoV spike protein and a C-terminal 8x His-tag. We stably transfected HEK 293 cells. Following expansion of the cells, the fusion protein was secreted from adherent cells into serum-free medium. Ni-NTA immobilized metal ion affinity chromatography (IMAC) purification resulted in very high protein purity, based on analysis by SDS-PAGE. The fusion protein was soluble and monodisperse, as confirmed by size-exclusion chromatography (SEC) and negative staining electron microscopy. Deglycosylation experiments confirmed the presence of N-linked glycosylations in the secreted protein. Complex formation with the peptidase domain of human angiotensin-converting enzyme 2 (ACE2), the receptor for the 2019-nCoV spike RBD, was confirmed by SEC, both for the YFP-fused spike RBD and for spike RBD alone, after removal of YFP by proteolytic cleavage. Possible applications for the fusion protein include binding studies on cells or , fluorescent labeling of potential virus-binding sites on cells, the use as an antigen for immunization studies or as a tool for the development of novel virus- or antibody-detection assays.
2019新型冠状病毒(2019-nCoV)是严重的、仍在全球范围内持续的冠状病毒病(COVID-19)大流行的病原体。与疫苗研发、改进检测方法以及全面了解病毒作用相关的研究需要高质量的重组病毒蛋白。2019-nCoV刺突(S)蛋白的受体结合域(RBD)含有二硫键和N-连接糖基化,因此通常通过分泌产生。在此,我们描述了一种用于表达和纯化黄色荧光蛋白(YFP)标记的2019-nCoV刺突RBD的构建体和方案。该融合蛋白存在于载体pcDNA 4/TO中,包含一个N端干扰素α2(IFNα2)信号肽、一个增强型黄色荧光蛋白(eYFP)、一个FLAG标签、一个人鼻病毒3C蛋白酶(HRV3C)切割位点、2019-nCoV刺突蛋白的RBD以及一个C端8x组氨酸标签。我们稳定转染了人胚肾293(HEK 293)细胞。细胞扩增后,融合蛋白从贴壁细胞分泌到无血清培养基中。基于十二烷基硫酸钠-聚丙烯酰胺凝胶电泳(SDS-PAGE)分析,镍-次氮基三乙酸(Ni-NTA)固定化金属离子亲和色谱(IMAC)纯化得到了非常高的蛋白纯度。通过尺寸排阻色谱(SEC)和负染电子显微镜证实,融合蛋白是可溶的且单分散的。去糖基化实验证实了分泌蛋白中存在N-连接糖基化。通过SEC证实,在通过蛋白水解切割去除YFP后,YFP融合的刺突RBD以及单独的刺突RBD均与人血管紧张素转换酶2(ACE2)的肽酶结构域(2019-nCoV刺突RBD的受体)形成复合物。该融合蛋白的可能应用包括细胞结合研究、细胞上潜在病毒结合位点的荧光标记、用作免疫研究的抗原或用作开发新型病毒或抗体检测方法的工具。